Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
STEM

Chemist Develops Potential Drug to Treat Type 2 Diabetes Without Harsh Side Effects

Sunday, July 12, 2020, By Dan Bernardi
Share
BioInspiredCollege of Arts and SciencesfacultyResearch and CreativeSTEM
head shot

Robert P. Doyle

Robert P. Doyle, the Laura J. and L. Douglas Meredith Professor in the Department of Chemistry in the College of Arts and Sciences and adjunct associate professor of medicine at SUNY Upstate Medical University, has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting and, in select cases, undesired weight loss. His research article, “Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,” has been published in the prestigious journal Cell Reports.

A common group of drugs used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do lower blood sugar levels in diabetic patients, their side effects include nausea, vomiting and weight loss.

Through a grant from the National Institutes of Health (NIH), Doyle and his team found a way to combine two molecules into a new substance that so far seems to lower blood sugar without those undesired side effects.

In technical terms, the team developed a new area of bioconjugation—a chemical technique used to couple two molecules. By binding together exendin-4 (Ex4), an FDA-approved GLP-1R agonist, to dicyanocobinamide (Cbi), which is a small piece of the complex vitamin B12 molecule, they produced Cbi-Ex4 in a technique they call “corrination.”

Data collected from testing Cbi-Ex4 in the musk shrew (Suncus murinus), the mammal used in this study due to its ability to vomit (rodents and many mammals lack that ability), revealed beneficial effects as evidenced by improved blood sugar levels during glucose tolerance tests and a profound reduction in vomiting compared to Ex4. Importantly, no weight loss was noted, again in stark contrast to the currently approved GLP-1R agonist, making this new drug ideal for patients who require glucoregulation without affecting their body mass index (BMI) levels. This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer or HIV, where weight-loss is counter-indicated.

The next step in the development of this groundbreaking drug is to move it through the pre-clinical phase into phase I human studies. Doyle and his team have submitted a new grant proposal to the NIH to fund this effort.

Doyle’s research was conducted in collaboration with the labs of Matt Hayes, professor in the Department of Psychiatry, University of Pennsylvania, and Bart C. De Jonghe, professor in the Department of Biobehavioral Health Sciences, University of Pennsylvania.

  • Author

Dan Bernardi

  • Recent
  • Expert Available to Discuss DOD Acceptance of Qatari Jet
    Thursday, May 22, 2025, By Vanessa Marquette
  • Snapshots From Route 66: One Student’s Journey to Newhouse LA
    Thursday, May 22, 2025, By Keith Kobland
  • Syracuse University 2025-26 Budget to Include Significant Expansion of Student Financial Aid
    Wednesday, May 21, 2025, By News Staff
  • Engaged Humanities Network Community Showcase Spotlights Collaborative Work
    Wednesday, May 21, 2025, By Dan Bernardi
  • Students Engaged in Research and Assessment
    Tuesday, May 20, 2025, By News Staff

More In STEM

University’s Dynamic Sustainability Lab and Ireland’s BiOrbic Sign MOU to Advance Markets for the Biobased Economy

This month at the All Island Bioeconomy Summit held in Co. Meath, Ireland, it was announced that BiOrbic, Research Ireland Centre for Bioeconomy, comprising 12 leading Irish research universities in Ireland, signed a joint memorandum of understanding (MOU) with the Dynamic Sustainability…

Professor Bing Dong Named as the Traugott Professor of Mechanical and Aerospace Engineering

The College of Engineering and Computer Science has named Bing Dong as the Traugott Professor of Mechanical and Aerospace Engineering. This endowed professorship is made possible by a 1998 gift from the late Fritz Traugott H’98 and his wife, Frances….

Physics Professor Honored for Efforts to Improve Learning, Retention

The Department of Physics in the College of Arts and Sciences (A&S) has made some big changes lately. The department just added an astronomy major approved by New York State and recently overhauled the undergraduate curriculum to replace traditional labs with innovative…

ECS Team Takes First Place in American Society of Civil Engineers Competition

Civil and environmental engineering student teams participated in the American Society of Civil Engineers (ASCE) Sustainable Solutions and Steel Bridge competitions during the 2025 Upstate New York-Canada Student Symposium, winning first place in the Sustainable Solutions competition. The symposium was…

Chloe Britton Naime Committed to Advocating for Improved Outcomes for Neurodivergent Individuals

Chloe Britton Naime ’25 is about to complete a challenging and rare dual major program in both mechanical engineering from the College of Engineering and Computer Science and neuroscience from the College of Arts and Sciences. Even more impressive? Britton…

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2025 Syracuse University News. All Rights Reserved.